Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × apatinib × Clear all

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Phase 2 Completed

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT07031154 2025-06-22

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04379739 2023-12-06

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05932264 2023-07-06

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04749394 2022-08-16

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Phase 2 Unknown

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04878107 2022-05-02

SABRE

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03256721 2021-02-08

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03267654 2020-08-03

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03758677 2020-07-23

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02515435 2017-08-18

The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02733107 2016-04-12

The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02540824 2015-09-04

Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01270386 2012-02-10

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms